AKSO Biopharmaceutical

AKSO Biopharmaceutical, founded in 2017, is a platform-based, clinical-stage biotech company developing breakthrough protein therapeutics. Its core innovation is the DEEP platform, designed to augment protein-protein interactions to create highly effective mono- and bispecific biologics, antibody-drug conjugates, and novel therapies. With a globally focused leadership team combining deep scientific and financial expertise, the company aims to accelerate drug discovery and address critical unmet medical needs in key therapeutic areas. AKSO is actively seeking strategic partnerships to advance its pipeline and expand its global impact.

Proprietary DEEP (Data-driven Engineering of Enhanced Proteins) platform designed to significantly augment protein-protein interactions for developing monospecific/bispecific biologics, ADCs, and novel protein therapeutics.

AKSO competes in crowded therapeutic areas dominated by large pharma and well-funded biotechs. Its differentiation relies on the purported superiority of its DEEP platform to create enhanced protein therapeutics, but it must demonstrate clear advantages over existing biologics and other protein engineering technologies.